From Stanford A.I. Research to San Francisco Healthcare Startup
On a mission to expand Direct-to-Intervention care
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
Viz.ai is a Direct-to-Intervention healthcare company that uses artificial intelligence and deep learning algorithms to analyze medical data and improve medical workflow. Direct-to-Intervention care advances information about treatable patients straight to the interventionalist. It removes much of the friction in today’s stroke workflow by providing the right information to the right doctor at the right time.
Viz.ai’s landmark product is the Viz.ai Direct-to-Intervention System for stroke. It aims to streamline stroke care by removing the friction involved in the identification, notification, transfer, and treatment of stroke patients. The Viz.ai Direct-to-Intervention System is currently CE Mark approved and is pending FDA approval.